<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName journalpublishing.dtd?>
<?SourceDTD.Version 2.3?>
<?ConverterInfo.XSLTName jp2nlmx2.xsl?>
<?ConverterInfo.Version 2?>
<front>
  <?epub May-5-2009?>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-id journal-id-type="hwp">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">2703957</article-id>
    <article-id pub-id-type="pmid">19417066</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gkp312</article-id>
    <article-id pub-id-type="publisher-id">gkp312</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Articles</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>SePreSA: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical–protein interactome</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Yang</surname>
          <given-names>Lun</given-names>
        </name>
        <xref ref-type="aff" rid="AFF1">
          <sup>1</sup>
        </xref>
        <xref ref-type="corresp" rid="COR1">*</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Luo</surname>
          <given-names>Heng</given-names>
        </name>
        <xref ref-type="aff" rid="AFF1">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Chen</surname>
          <given-names>Jian</given-names>
        </name>
        <xref ref-type="aff" rid="AFF1">
          <sup>1</sup>
        </xref>
        <xref ref-type="aff" rid="AFF1">
          <sup>2</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Xing</surname>
          <given-names>Qinghe</given-names>
        </name>
        <xref ref-type="aff" rid="AFF1">
          <sup>2</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>He</surname>
          <given-names>Lin</given-names>
        </name>
        <xref ref-type="aff" rid="AFF1">
          <sup>2</sup>
        </xref>
        <xref ref-type="aff" rid="AFF1">
          <sup>3</sup>
        </xref>
        <xref ref-type="corresp" rid="COR1">*</xref>
      </contrib>
    </contrib-group>
    <aff id="AFF1"><sup>1</sup>Bio-X Center, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai 200030, <sup>2</sup>Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032 and <sup>3</sup>Institute for Nutritional Sciences, Shanghai Institutes of Biological Sciences, Chinese Academy of Sciences, Shanghai, 200031, PR China</aff>
    <author-notes>
      <corresp id="COR1">*To whom correspondence should be addressed. Tel: <phone>+86 21 6293 3338</phone>, ext. <phone>8108</phone>; Fax: <fax>+86 21 6293 2059</fax>; Email: <email>lunyang@gmail.com</email>. Correspondence may also be addressed to Lin He. Tel: <phone>0086-(0)21-62833148</phone>; Fax: <fax>0086-(0)21-32260640</fax>; Email: <email>helinhelin@gmail.com</email></corresp>
      <fn>
        <p>The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="ppub">
      <day>1</day>
      <month>7</month>
      <year>2009</year>
    </pub-date>
    <pub-date pub-type="epub">
      <day>5</day>
      <month>5</month>
      <year>2009</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>5</day>
      <month>5</month>
      <year>2009</year>
    </pub-date>
    <!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. -->
    <volume>37</volume>
    <issue>Web Server issue</issue>
    <fpage>W406</fpage>
    <lpage>W412</lpage>
    <history>
      <date date-type="received">
        <day>28</day>
        <month>1</month>
        <year>2009</year>
      </date>
      <date date-type="rev-recd">
        <day>6</day>
        <month>4</month>
        <year>2009</year>
      </date>
      <date date-type="accepted">
        <day>18</day>
        <month>4</month>
        <year>2009</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2009 The Author(s)</copyright-statement>
      <copyright-year>2009</copyright-year>
      <license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/uk/">
        <license-p><!--CREATIVE COMMONS-->This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/uk/">http://creativecommons.org/licenses/by-nc/2.0/uk/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <abstract>
      <p>Serious adverse drug reactions (SADRs) are caused by unexpected drug–human protein interactions, and some polymorphisms within binding pockets make the population carrying these polymorphisms susceptible to SADR. Predicting which populations are likely to be susceptible to SADR will not only strengthen drug safety, but will also assist enterprises to adjust R&amp;D and marketing strategies. Making such predictions has recently been facilitated by the introduction of a web server named SePreSA. The server has a comprehensive collection of the structural models of nearly all the well known SADR targets. Once a drug molecule is submitted, the scale of its potential interaction with multi-SADR targets is calculated using the DOCK program. The server utilizes a 2-directional <italic>Z</italic>-transformation scoring algorithm, which computes the relative drug–protein interaction strength based on the docking-score matrix of a chemical–protein interactome, thus achieve greater accuracy in prioritizing SADR targets than simply using dock scoring functions. The server also suggests the binding pattern of the lowest docking score through 3D visualization, by highlighting and visualizing amino acid residues involved in the binding on the customer's browser. Polymorphism information for different populations for each of the interactive residues will be displayed, helping users to deduce the population-specific susceptibility of their drug molecule. The server is freely available at <ext-link ext-link-type="uri" xlink:href="http://SePreSA.Bio-X.cn/">http://SePreSA.Bio-X.cn/</ext-link>.</p>
    </abstract>
  </article-meta>
</front>
<body>
  <sec>
    <title>INTRODUCTION</title>
    <p>Drug effect varies among populations. The Japanese population, for instance, exhibit a more rapid response to the lung cancer therapy gefitinib (<xref ref-type="bibr" rid="B1">1</xref>), since polymorphisms within the binding pocket of the drug target increase sensitivity to inhibition by the drug (<xref ref-type="bibr" rid="B2 B3 B4">2–4</xref>), and these polymorphisms occur more frequently in Asian populations. Serious adverse drug reaction (SADR), an unwanted drug effect, has been an urgent world-wide problem, particularly as tragedies triggered by Vioxx® (<xref ref-type="bibr" rid="B5">5</xref>) and Avandia® (<xref ref-type="bibr" rid="B6">6</xref>) these years. SADRs, especially type B adverse drug reactions (ADRs) (<xref ref-type="bibr" rid="B7">7</xref>), are mainly caused by unexpected interactions of the drug with the SADR targets (<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>), and some polymorphisms within the binding pocket make the population carrying these polymorphisms more susceptible to harmful effects. If drug companies had been able to identify the sensitive population earlier, they should have altered their R&amp;D and marketing strategy beforehand to lower the rate of SADR and to avoid lawsuits. Furthermore, such prediction would suggest candidate polymorphisms for SADR association studies (<xref ref-type="bibr" rid="B10">10</xref>), provide hints for interpreting genome-wide association results for SADR and provide primers for functional studies of the SADR mechanism.</p>
    <p>Three steps could lead to the prediction of susceptible populations. First, SADR targets which tend to be bound by the compound in question should be prioritized. Second, the conformation of chemical–protein bindings and the interactive residues should be identified. Third, polymorphisms altering drug binding and their minor allele frequency among different populations could then be characterized. Docking programs could be applied to perform the above steps, as the program can not only measure the binding strength of a ligand to a set of SADR targets (<xref ref-type="bibr" rid="B11">11</xref>), but can also deliver the binding conformation. Consequently, residues involved in the interaction together with information on their polymorphisms in different populations can be identified. For the first time, these three steps have been integrated into a server named SePreSA. The server computes a relative drug–protein interaction score from a scoring matrix of a chemical–protein interactome (CPI) to prioritize SADR targets which might be affinitive with the user's compound. Considerable specificity and sensitivity in predicting chemical–protein bindings have been achieved by the use of this scoring algorithm. The 3D visualization of the binding pattern is provided, with interactive residues highlighted and the population information presented to the client.</p>
  </sec>
  <sec sec-type="methods">
    <title>METHODS</title>
    <sec>
      <title>Target set for the web server</title>
      <p>To make a comprehensive collection of the structural models of the well known SADR targets, we chose all the available structures from PDB which are known to mediate ADRs. The target set includes major phases I and II drug-metabolite enzymes, several types of human MHC I proteins mediating drug hypersensitivity and the pharmacodynamic proteins chosen from DITOP (<xref ref-type="bibr" rid="B12">12</xref>) and DART (<xref ref-type="bibr" rid="B13">13</xref>) database. All structure models chosen should accord with the following criteria: (i) the species of the proteins is limited to <italic>Homo Sapiens</italic>; (ii) the protein must contain at least one ligand embedded in it to define the functional site; (iii) no missing residues should be found around this site; and (iv) ligands at the surface of the protein are not acceptable. Now, it contains 91 proteins with 115 ligand-binding site defined. For each ADR target, residues within a 10 Å distance from the ligand were defined as the bioactive pocket of the protein, and balls with a radius ranging from 1.1 to 1.4 Å were generated to fill in the pocket. A grid box was made at 3–5 Å distant from the ‘cloud’ of the balls. Certain water molecules or metal ions play important roles to the protein function, so we used the scientific judgment to decide whether to keep them. The key residue ionization state has been assigned considering the most probable one at the physiological pH, i.e. carboxyl is usually ionized; lysine and arginine residues are protonated; aspartate and glutamate residues are deprotonated; histidine residues are half protonated. We controlled these ionization state using Chimera (<xref ref-type="bibr" rid="B14">14</xref>) when preparing the targets. The polymorphism information for each ADR targets is derived from Uniprot (<xref ref-type="bibr" rid="B15">15</xref>). We will continue to update ADR targets in SePreSA, and users can subscribe to our updates through RSS feeds.</p>
    </sec>
    <sec>
      <title>Dataset for the prediction evaluation</title>
      <p>We singled out all co-crystallized ligands embedded in all structures of SePreSA. The antagonists taking up the functional site of the protein were chosen as the probe molecule. Pockets without co-crystallized ligands were excluded, leaving 79 proteins for the construction of the CPI. The molecular probes were submitted through the SePreSA interface to perform an <italic>in silico</italic> hybridization, generating an interactome of 86 ligands towards 79 protein pockets in the form of a docking-score matrix of 79 × 86 elements. Docking scores ≥ 0 were treated as missing values.</p>
    </sec>
    <sec>
      <title>The prediction evaluation</title>
      <p>An algorithm named 2-directional <italic>Z</italic>-transformation (2DIZ) was applied to process the original docking-score matrix. Here, <italic>X</italic><italic><sub>ij</sub></italic> represents the docking scores of ligand <italic>j</italic> to protein <italic>i</italic>. The <italic>Z</italic>-score was calculated as:
<disp-formula><graphic xlink:href="gkp312um1"/></disp-formula>
where
<disp-formula><graphic xlink:href="gkp312um2"/></disp-formula>
<disp-formula><graphic xlink:href="gkp312um3"/></disp-formula>
Here, <italic>N<sub>j</sub></italic> equaled 86 minus the number of missing values of ligand <italic>j</italic>. Thus, a <italic>Z</italic>-score matrix of 79 × 86 elements was generated. The vector for each protein was then normalized to a mean of zero and a standard deviation of one, generating a 79 × 86 <italic>Z</italic>′-score matrix. These three matrixes allowed us to investigate the distributions of docking scores, <italic>Z</italic>-scores and <italic>Z</italic>′-scores on true ligand–protein bindings and the unidentified bindings. Here, we defined the original bindings in PDB structures as the gold standard, and the ability of these three scoring matrixes to predict ligand–protein bindings were presented in ROC curves.</p>
    </sec>
  </sec>
  <sec>
    <title>INPUT AND OUTPUT</title>
    <p>Users need to upload a drug molecule in mol2 format. A manual at <ext-link ext-link-type="uri" xlink:href="http://sepresa.bio-x.cn/?page=generatemol2file">http://sepresa.bio-x.cn/?page=generatemol2file</ext-link> will instruct users in preparing their mol2 files. The server cannot accept molecules in SMILES and mol format, since the ionization state of the drugs have to be specified by users but these two formats cannot include the ionization information of the molecules. The format suitability is checked and its interactome towards all SADR targets was calculated using DOCK (<xref ref-type="bibr" rid="B16">16</xref>). The task usually takes up to about 6 h for a molecule, and an email will be sent on completion. The outputs comprise the following three elements.
<list list-type="alpha-lower"><list-item><p>SADR targets that tend to interact with your molecule will be prioritized.</p></list-item><list-item><p>For each SADR target, binding patterns of the lowest docking score and amino acid residues that interact with your molecule will be highlighted in Jmol (<xref ref-type="bibr" rid="B17">17</xref>) applet.</p></list-item><list-item><p>Polymorphism information such as minor allele frequencies among different populations for each of the interactive residues will be displayed.</p></list-item></list>
</p>
  </sec>
  <sec sec-type="results">
    <title>RESULTS</title>
    <sec>
      <title>Prediction of the true and unidentified bindings</title>
      <p>We compared the prediction power using different CPI scoring matrixes (<xref ref-type="fig" rid="F1">Figure 1</xref>). The docking-score matrix performed poorest among the three, the area under the curve (AUC) being only 0.62 (<ext-link ext-link-type="uri" xlink:href="http://nar.oxfordjournals.org/cgi/content/full/gkp312/DC1">Supplementary Table S1</ext-link>), and the lower bound of 95% confidence interval (95% CI) 0.56, which was close to that for a random selection. With the 2DIZ algorithm, however, the AUC reached 0.82 (95%CI: 0.78–0.87). Though performing slightly worse than the <italic>Z</italic>′-score matrix, the <italic>Z</italic>-transformation achieved a better performance than simply using the docking-score matrix.
<fig id="F1" position="float"><label>Figure 1.</label><caption><p>The ROC curves of different CPI-scoring matrixes in predicting true and unidentified.</p></caption><graphic xlink:href="gkp312f1"/></fig></p>
      <p>The distribution of <italic>Z</italic>′-scores between true and unidentified bindings are compared in <ext-link ext-link-type="uri" xlink:href="http://nar.oxfordjournals.org/cgi/content/full/gkp312/DC1">Supplementary Figure S1a</ext-link>. <italic>Z</italic>′-score for ∼80% of the true bindings, compared with only 30% of the unidentified bindings, were &lt;–0.5 (<ext-link ext-link-type="uri" xlink:href="http://nar.oxfordjournals.org/cgi/content/full/gkp312/DC1">Supplementary Table S2</ext-link>). Hence, we set a <italic>Z</italic>′-score threshold of –0.5 to highlight the putative bindings of users’ drugs towards SADR targets, and the sensitivity, specificity and the overall accuracy were 0.80, 0.71 and 0.71, respectively. Docking-score distributions of the true bindings did not seem to be significantly different from those of the unidentified bindings (<ext-link ext-link-type="uri" xlink:href="http://nar.oxfordjournals.org/cgi/content/full/gkp312/DC1">Supplementary Figure S1b</ext-link>).</p>
      <p>The sensitivity of the <italic>Z</italic>′-score-based prediction was diminished by the high <italic>Z</italic>′-score of several true bindings. In most circumstances, these false negatives were due to the large size of the probe. Glutathione, a relatively large molecule, could not be docked into 20% of the pockets, resulting in a number of missing values. Consequently, its <italic>Z</italic>-score vector did not fully reflect its binding profile for all pockets, causing a potential bias in <italic>Z</italic>′-score of for its co-crystallized enzyme (PDB ID: 11GS). Another reason for the false negative lay in the poor selectivity of the probe. Ethyl dihydrogen phosphate, a small molecule which could possibly crawl into the pocket of all the proteins, did not appear to be selectively affinitive to its co-crystallized protein (1XLV), and thus its <italic>Z</italic>′-score for 1XLV was not noticeably low.</p>
      <p>The specificity of the <italic>Z</italic>′-score-based prediction might also be much higher than current results, because some of the unidentified bindings, whose <italic>Z</italic>′-scores were significantly &lt;–0.5, might occur <italic>per se</italic>, but were regarded as false positives. For example, the <italic>Z</italic>′-score between catechol <italic>O</italic>-methyltransferase (3BWY) and <italic>S</italic>-adenosyl-<sc>l</sc>-homocysteine (SAH) was –3.1. SAH was structurally similar to <italic>S</italic>-adenosylmethionine (SAM), which was the original ligand embedded in 3BWY. On the other hand, SAH was originally embedded in nicotinamide <italic>N</italic>-methyltransferase (2IIP), which belongs to the family of 3BWY. Hence, SAH is very likely to bind to 3BWY i. If this is true, the strong signal indicated by the low <italic>Z</italic>′-score of the SAH–3BWY interaction could indicate that the 2DIZ scoring algorithm is capable of prioritizing unexpected bindings.</p>
    </sec>
    <sec>
      <title>Applying 2DIZ algorithm to the web server</title>
      <p>The SePreSA server uses 2DIZ algorithm to prioritize SADR targets of the user's molecule. The prediction mechanism is based on a user-oriented interactome, which calculates the <italic>Z</italic>′-score of the current molecule from the interactome formed by all molecules submitted by this user, no matter when and where these previous molecules are submitted. Hence, the more molecule a user submits, the more comprehensive CPI profile for each ADR targets he will retrieve.</p>
    </sec>
    <sec>
      <title>Case study 1</title>
      <p>Serious cutaneous reaction (SCR) triggered by sulfamethoxazole (SMX) might be mediated by the MHC I family members (<xref ref-type="bibr" rid="B18">18</xref>). After submitting SMX to SePreSA, we found unexpectedly that the HLA class I histocompatibility antigen, Cw-4 alpha chain (MHC I Cw*4) ranked in the fourth among the total 70 SADR target pockets. By visualizing the binding conformation of the SMX molecule to MHC I Cw*4 in the binding-information page (<ext-link ext-link-type="uri" xlink:href="http://sepresa.bio-x.cn/?reactionid=5069">http://sepresa.bio-x.cn/?reactionid=5069</ext-link>), we found that it tended to ‘root’ at the Y bed of the antigen presentation groove. The identification of HLA-C gene (Cw*4 allele) as the mediator of SCR had been validated in several former studies, from which it was confirmed that the SCR could only be triggered by SMX in presence of MHC I (Cw*4) (<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref>).</p>
      <p>To our knowledge, no other research has ever disclosed such direct binding model before the results given by SePreSA. Although the identification of this risk allele needs further validation, several ‘wet’ observations support this model. For example, the presentation of SMX parent drug displayed a direct, non-covalent binding fashion to the ‘empty’ presentation groove of MHC I (<xref ref-type="bibr" rid="B21">21</xref>). Von Greyerz <italic>et al</italic>. (<xref ref-type="bibr" rid="B19">19</xref>) discovered that most T cell clones exhibited the ‘MHC-allele restricted drug-specific recognition’ stimulated by SMX parent drug. Nassif (<xref ref-type="bibr" rid="B20">20</xref>) also uncovered that blister fluid T lymphocytes, which were derived from a patient suffering SMX-induced SCR, could be cytotoxic only when SMX is present in the cells with Cw*4 allele.</p>
    </sec>
    <sec>
      <title>Case study 2</title>
      <p>The incidence of neuropsychiatric disorder triggered by oseltamivir (Tamiflu®) varies among populations. The Japanese population demonstrates a higher SADR rate than predominantly European-derived populations for this drug (<ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/ohrms/dockets/AC/05/briefing/2005-4180b_06_01_Tamiflu%20AE_reviewed.pdf">http://www.fda.gov/ohrms/dockets/AC/05/briefing/2005-4180b_06_01_Tamiflu%20AE_reviewed.pdf</ext-link>). The SADR target of oseltamivir (HsNEU2) (<xref ref-type="bibr" rid="B8">8</xref>) was also included in our pocket set. We, therefore, submit the active form of the drug, oseltamivir carboxylate, to ascertain whether the HsNEU2 and the susceptible population could be prioritized. The molecule achieved a <italic>Z</italic>-score of –1.72 with HsNEU2, the second lowest <italic>Z</italic>-score for 70 pockets, and a <italic>Z</italic>′-score of –0.92 temporarily, which was much lower than the true binding threshold of –0.5. By then clicking on the ‘Result’ button, the binding conformation and the interactive residues within 6.4 Å of the drug were presented (<xref ref-type="fig" rid="F2">Figure 2</xref>), together with a polymorphism (rs2233385) highlighted among these residues. By clicking on the ‘Show Report’ button, we found that this polymorphism only occurred in Asian population but not in European and African–American populations (<ext-link ext-link-type="uri" xlink:href="http://nar.oxfordjournals.org/cgi/content/full/gkp312/DC1">Supplementary Table S3</ext-link>). These results suggested that Asian population might be more sensitive to oseltamivir-induced SADR, for which rs2233385 might be responsible.
<fig id="F2" position="float"><label>Figure 2.</label><caption><p>Binding conformation of oseltamivir to HsNEU2 and the interactive residues within 6.4 Å of the drug. Among all these residues, the R41Q polymorphism (rs2233385) was highlighted.</p></caption><graphic xlink:href="gkp312f2"/></fig></p>
      <p>Such prediction potential will assist further mechanism studies and genetic association studies on HsNEU2-mediated SADR. If all these facts are approved, the manufacturer of oseltamivir, for example, could improve drug safety through changing the marketing strategy or utilizing pharmacogenomic tests. With the benefit of SePreSA predictions during the early development phase, manufacturers would have the opportunity to redesign or modify the drug in order to weaken such unexpected binding, or they might even give up the Asian market to avoid unexpected lawsuits.</p>
    </sec>
  </sec>
  <sec sec-type="discussion">
    <title>DISCUSSION</title>
    <p>Though a lot of downstream events occur when a drug is added to the cell culture, it is undisputed that direct chemical–protein interaction is the primary and the vital factor in drug effects. So, identifying the true bindings of unexpected drug–protein interactions is fundamental in pharmacodynamic research and in the prediction of effects including SADR. Several techniques such as BIACORE® biosensors (<xref ref-type="bibr" rid="B22">22</xref>) and drug affinity pull-down (<xref ref-type="bibr" rid="B23">23</xref>) can be used to assess such interactions. However, these techniques do not match the dramatic progress achieved by transcriptomics, metabolomics and proteomics. The concept of docking a small molecule into a multi-protein set to prioritize unexpected bindings was first put forward by Chen <italic>et al</italic>. (<xref ref-type="bibr" rid="B11">11</xref>). Several follow-up studies have pursued this logic in prioritizing true targets (<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>), namely that the lower the docking score achieved, the more this binding tends to happen. But this approach does not offer a systematic evaluation of relevant specificity and sensitivity. The docking score might not be sufficient to evaluate the binding strength, e.g. if the docking score of drug A to protein P1 is much lower than A to P2, there is no certainty that P1 is more affinitive to A than P2. However, by considering the mean and the standard deviation of the score vectors upon the two proteins towards multiligands, a more informed judgment can be made.</p>
    <p>SePreSA, is the first system to utilize the drug–protein interaction landscape at an interactome level to help users make sound decisions. Although the docking-score matrix of the test CPI now contained 79 × 86 elements, from which the magnitude at either rows or columns did not seem to be very impressive, it already had a total of about 79 × 86 = 6794 ligand–protein pairs to be identified. So, we believe that the classification performances generated at such amount of data can reflect the true performance of <italic>Z</italic>′-scores to some extent. To our knowledge, this is not only the first, but also the largest evaluation in the target ‘fishing’ methodology using molecular docking in company with clear reported sensitivity, specificity and accuracy data. The experience gathered from using this system also suggests that the use of relative scores from the ‘-omics’ viewpoint can achieve much greater accuracy than simply comparing the docking scores of the two independent interactions. Our algorithm might also inspire the existing virtual screening methodologies. If the interactome profiles of the library molecules towards multiproteins are considered, more accurate results can be achieved.</p>
    <p>In this research, our underlying logic was that drug effects would necessarily change when the binding of a drug to its target is altered, and polymorphisms involved in this direct interaction would necessarily change the binding. We have seen that, although drug response is a complex trait (<xref ref-type="bibr" rid="B26">26</xref>) mediated by multiple genes, some single polymorphism can also have pronounced effects on drug response. To our knowledge, they all alter the binding conformations of direct drug–protein interactions. Examples include the T790M in the gefitinib binding pocket of EGFR (<xref ref-type="bibr" rid="B4">4</xref>); the T164I within the epinephrine binding pocket of β<sub>2</sub>-adrenergic receptor (<xref ref-type="bibr" rid="B27">27</xref>); and the polymorphism within the binding pocket of STI-571 to c-Abl (<xref ref-type="bibr" rid="B28">28</xref>). The empirical threshold of 6.4 Å was set to highlight the putative interactive sites according to the distance distribution of drugs to the polymorphism sites that alter drug binding. So SePreSA cannot predict every polymorphism that alters drug binding, but it can predict the interactive residues within the 6.4 Å ‘cloud’, whose polymorphism information are available. Both the premise and the empirical threshold will be more thoroughly evaluated in follow-up research.</p>
  </sec>
  <sec sec-type="conclusions">
    <title>CONCLUSION</title>
    <p>
      <list list-type="alpha-lower">
        <list-item>
          <p>The core of the SePreSA server is the 2DIZ scoring algorithm. It can accurately predict bindings of a chemical towards multiproteins, and hence could be applied in prioritizing SADR targets.</p>
        </list-item>
        <list-item>
          <p>By using SePreSA, drug enterprises can identify the putative populations that appear sensitive to their drugs, hence early decision during the R&amp;D stage can be made and safety can be promoted in the marketed products.</p>
        </list-item>
        <list-item>
          <p>SADR genetic researchers could find candidate polymorphisms from SePreSA for their SADR association studies. The server could also help to interpret genome-wide association results for SADR and enhance functional studies of the SADR mechanism.</p>
        </list-item>
      </list>
    </p>
  </sec>
  <sec>
    <title>SUPPLEMENTARY DATA</title>
    <p><ext-link ext-link-type="uri" xlink:href="http://nar.oxfordjournals.org/cgi/content/full/gkp312/DC1">Supplementary Data</ext-link> are available at NAR Online.</p>
  </sec>
  <sec>
    <title>FUNDING</title>
    <p>Major State Basic Research Development Program (2006CB910601) and National Key Technology R&amp;D Program (2006BAI05A05). Funding for open access charge: China Postdoctoral Science Foundation (20070420660) and the Shanghai Postdoctoral Science Foundation (No. 61444).</p>
    <p><italic>Conflict of interest statement</italic>. None declared.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="PMC_1" content-type="local-data">
      <caption>
        <title>[Supplementary Data]</title>
      </caption>
      <media mimetype="text" mime-subtype="html" xlink:href="gkp312_index.html"/>
      <media xlink:role="associated-file" mimetype="application" mime-subtype="msword" xlink:href="gkp312_nar-00174-web-b-2009-File004.doc"/>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack>
    <title>ACKNOWLEDGEMENTS</title>
    <p>We thank Dr Leming Shi, Dr Janet Woodcock and Dr Zichun Hua for their helpful suggestions and comments on SADR genetics. We are grateful to the developers of the DOCK program and Jmol applet.</p>
  </ack>
  <ref-list>
    <title>REFERENCES</title>
    <ref id="B1">
      <label>1</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Fukuoka</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Yano</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Giaccone</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Tamura</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Nakagawa</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Douillard</surname>
            <given-names>JY</given-names>
          </name>
          <name>
            <surname>Nishiwaki</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Vansteenkiste</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Kudoh</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Rischin</surname>
            <given-names>D</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]</article-title>
        <source>J. Clin. Oncol.</source>
        <year>2003</year>
        <volume>21</volume>
        <fpage>2237</fpage>
        <lpage>2246</lpage>
        <pub-id pub-id-type="pmid">12748244</pub-id>
      </element-citation>
    </ref>
    <ref id="B2">
      <label>2</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lynch</surname>
            <given-names>TJ</given-names>
          </name>
          <name>
            <surname>Bell</surname>
            <given-names>DW</given-names>
          </name>
          <name>
            <surname>Sordella</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Gurubhagavatula</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Okimoto</surname>
            <given-names>RA</given-names>
          </name>
          <name>
            <surname>Brannigan</surname>
            <given-names>BW</given-names>
          </name>
          <name>
            <surname>Harris</surname>
            <given-names>PL</given-names>
          </name>
          <name>
            <surname>Haserlat</surname>
            <given-names>SM</given-names>
          </name>
          <name>
            <surname>Supko</surname>
            <given-names>JG</given-names>
          </name>
          <name>
            <surname>Haluska</surname>
            <given-names>FG</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</article-title>
        <source>N. Engl. J. Med.</source>
        <year>2004</year>
        <volume>350</volume>
        <fpage>2129</fpage>
        <lpage>2139</lpage>
        <pub-id pub-id-type="pmid">15118073</pub-id>
      </element-citation>
    </ref>
    <ref id="B3">
      <label>3</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Paez</surname>
            <given-names>JG</given-names>
          </name>
          <name>
            <surname>Janne</surname>
            <given-names>PA</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>JC</given-names>
          </name>
          <name>
            <surname>Tracy</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Greulich</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Gabriel</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Herman</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Kaye</surname>
            <given-names>FJ</given-names>
          </name>
          <name>
            <surname>Lindeman</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Boggon</surname>
            <given-names>TJ</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy</article-title>
        <source>Science</source>
        <year>2004</year>
        <volume>304</volume>
        <fpage>1497</fpage>
        <lpage>1500</lpage>
        <pub-id pub-id-type="pmid">15118125</pub-id>
      </element-citation>
    </ref>
    <ref id="B4">
      <label>4</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kobayashi</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Boggon</surname>
            <given-names>TJ</given-names>
          </name>
          <name>
            <surname>Dayaram</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Janne</surname>
            <given-names>PA</given-names>
          </name>
          <name>
            <surname>Kocher</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Meyerson</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Johnson</surname>
            <given-names>BE</given-names>
          </name>
          <name>
            <surname>Eck</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Tenen</surname>
            <given-names>DG</given-names>
          </name>
          <name>
            <surname>Halmos</surname>
            <given-names>B</given-names>
          </name>
        </person-group>
        <article-title>EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</article-title>
        <source>N. Engl. J. Med.</source>
        <year>2005</year>
        <volume>352</volume>
        <fpage>786</fpage>
        <lpage>792</lpage>
        <pub-id pub-id-type="pmid">15728811</pub-id>
      </element-citation>
    </ref>
    <ref id="B5">
      <label>5</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Furberg</surname>
            <given-names>CD</given-names>
          </name>
        </person-group>
        <article-title>Adverse cardiovascular effects of rofecoxib</article-title>
        <source>N. Engl. J. Med.</source>
        <year>2006</year>
        <volume>355</volume>
        <fpage>204</fpage>
        <lpage>205</lpage>
        <pub-id pub-id-type="pmid">16838442</pub-id>
      </element-citation>
    </ref>
    <ref id="B6">
      <label>6</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Nissen</surname>
            <given-names>SE</given-names>
          </name>
          <name>
            <surname>Wolski</surname>
            <given-names>K</given-names>
          </name>
        </person-group>
        <article-title>Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes</article-title>
        <source>N. Engl. J. Med.</source>
        <year>2007</year>
        <volume>356</volume>
        <fpage>2457</fpage>
        <lpage>2471</lpage>
        <pub-id pub-id-type="pmid">17517853</pub-id>
      </element-citation>
    </ref>
    <ref id="B7">
      <label>7</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wilke</surname>
            <given-names>RA</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>DW</given-names>
          </name>
          <name>
            <surname>Roden</surname>
            <given-names>DM</given-names>
          </name>
          <name>
            <surname>Watkins</surname>
            <given-names>PB</given-names>
          </name>
          <name>
            <surname>Flockhart</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Zineh</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Giacomini</surname>
            <given-names>KM</given-names>
          </name>
          <name>
            <surname>Krauss</surname>
            <given-names>RM</given-names>
          </name>
        </person-group>
        <article-title>Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges</article-title>
        <source>Nat. Rev. Drug Discov.</source>
        <year>2007</year>
        <volume>6</volume>
        <fpage>904</fpage>
        <lpage>916</lpage>
        <pub-id pub-id-type="pmid">17971785</pub-id>
      </element-citation>
    </ref>
    <ref id="B8">
      <label>8</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>CY</given-names>
          </name>
          <name>
            <surname>Yu</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Ye</surname>
            <given-names>ZQ</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>He</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>XM</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Luo</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Gu</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Zheng</surname>
            <given-names>X</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A nonsynonymous SNP in human cytosolic sialidase in a small Asian population results in reduced enzyme activity: potential link with severe adverse reactions to oseltamivir</article-title>
        <source>Cell Res.</source>
        <year>2007</year>
        <volume>17</volume>
        <fpage>357</fpage>
        <lpage>362</lpage>
        <pub-id pub-id-type="pmid">17426694</pub-id>
      </element-citation>
    </ref>
    <ref id="B9">
      <label>9</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hamasaki</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Rando</surname>
            <given-names>RR</given-names>
          </name>
        </person-group>
        <article-title>Specific binding of aminoglycosides to a human rRNA construct based on a DNA polymorphism which causes aminoglycoside-induced deafness</article-title>
        <source>Biochemistry</source>
        <year>1997</year>
        <volume>36</volume>
        <fpage>12323</fpage>
        <lpage>12328</lpage>
        <pub-id pub-id-type="pmid">9315872</pub-id>
      </element-citation>
    </ref>
    <ref id="B10">
      <label>10</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Oh</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Ban</surname>
            <given-names>MR</given-names>
          </name>
          <name>
            <surname>Miskie</surname>
            <given-names>BA</given-names>
          </name>
          <name>
            <surname>Pollex</surname>
            <given-names>RL</given-names>
          </name>
          <name>
            <surname>Hegele</surname>
            <given-names>RA</given-names>
          </name>
        </person-group>
        <article-title>Genetic determinants of statin intolerance</article-title>
        <source>Lipids Health Dis.</source>
        <year>2007</year>
        <volume>6</volume>
        <fpage>7</fpage>
        <pub-id pub-id-type="pmid">17376224</pub-id>
      </element-citation>
    </ref>
    <ref id="B11">
      <label>11</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>YZ</given-names>
          </name>
          <name>
            <surname>Zhi</surname>
            <given-names>DG</given-names>
          </name>
        </person-group>
        <article-title>Ligand-protein inverse docking and its potential use in the computer search of protein targets of a small molecule</article-title>
        <source>Proteins</source>
        <year>2001</year>
        <volume>43</volume>
        <fpage>217</fpage>
        <lpage>226</lpage>
        <pub-id pub-id-type="pmid">11276090</pub-id>
      </element-citation>
    </ref>
    <ref id="B12">
      <label>12</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>JX</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>WJ</given-names>
          </name>
          <name>
            <surname>Zeng</surname>
            <given-names>JH</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>WH</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Han</surname>
            <given-names>BC</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>QF</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>YZ</given-names>
          </name>
          <name>
            <surname>Ji</surname>
            <given-names>ZL</given-names>
          </name>
        </person-group>
        <article-title>DITOP: drug-induced toxicity related protein database</article-title>
        <source>Bioinformatics</source>
        <year>2007</year>
        <volume>23</volume>
        <fpage>1710</fpage>
        <lpage>1712</lpage>
        <pub-id pub-id-type="pmid">17463030</pub-id>
      </element-citation>
    </ref>
    <ref id="B13">
      <label>13</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ji</surname>
            <given-names>ZL</given-names>
          </name>
          <name>
            <surname>Han</surname>
            <given-names>LY</given-names>
          </name>
          <name>
            <surname>Yap</surname>
            <given-names>CW</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>LZ</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>YZ</given-names>
          </name>
        </person-group>
        <article-title>Drug Adverse Reaction Target Database (DART): proteins related to adverse drug reactions</article-title>
        <source>Drug Saf.</source>
        <year>2003</year>
        <volume>26</volume>
        <fpage>685</fpage>
        <lpage>690</lpage>
        <pub-id pub-id-type="pmid">12862503</pub-id>
      </element-citation>
    </ref>
    <ref id="B14">
      <label>14</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pettersen</surname>
            <given-names>EF</given-names>
          </name>
          <name>
            <surname>Goddard</surname>
            <given-names>TD</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>CC</given-names>
          </name>
          <name>
            <surname>Couch</surname>
            <given-names>GS</given-names>
          </name>
          <name>
            <surname>Greenblatt</surname>
            <given-names>DM</given-names>
          </name>
          <name>
            <surname>Meng</surname>
            <given-names>EC</given-names>
          </name>
          <name>
            <surname>Ferrin</surname>
            <given-names>TE</given-names>
          </name>
        </person-group>
        <article-title>UCSF Chimera–a visualization system for exploratory research and analysis</article-title>
        <source>J. Comput. Chem.</source>
        <year>2004</year>
        <volume>25</volume>
        <fpage>1605</fpage>
        <lpage>1612</lpage>
        <pub-id pub-id-type="pmid">15264254</pub-id>
      </element-citation>
    </ref>
    <ref id="B15">
      <label>15</label>
      <element-citation publication-type="journal">
        <collab>The UniProt Consortium</collab>
        <article-title>The Universal Protein Resource (UniProt)</article-title>
        <source>Nucleic Acids Res</source>
        <year>2009</year>
        <volume>37</volume>
        <fpage>D169</fpage>
        <lpage>D174</lpage>
        <pub-id pub-id-type="pmid">18836194</pub-id>
      </element-citation>
    </ref>
    <ref id="B16">
      <label>16</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ewing</surname>
            <given-names>TJ</given-names>
          </name>
          <name>
            <surname>Makino</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Skillman</surname>
            <given-names>GA</given-names>
          </name>
          <name>
            <surname>Kuntz</surname>
            <given-names>ID</given-names>
          </name>
        </person-group>
        <article-title>DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases</article-title>
        <source>J. Comput. Aided Mol. Des.</source>
        <year>2001</year>
        <volume>15</volume>
        <fpage>411</fpage>
        <lpage>428</lpage>
        <pub-id pub-id-type="pmid">11394736</pub-id>
      </element-citation>
    </ref>
    <ref id="B17">
      <label>17</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cammer</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>SChiSM2: creating interactive web page annotations of molecular structure models using Jmol</article-title>
        <source>Bioinformatics</source>
        <year>2007</year>
        <volume>23</volume>
        <fpage>383</fpage>
        <lpage>384</lpage>
        <pub-id pub-id-type="pmid">17204464</pub-id>
      </element-citation>
    </ref>
    <ref id="B18">
      <label>18</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Schnyder</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Mauri-Hellweg</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Zanni</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Bettens</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Pichler</surname>
            <given-names>WJ</given-names>
          </name>
        </person-group>
        <article-title>Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones</article-title>
        <source>J. Clin. Invest.</source>
        <year>1997</year>
        <volume>100</volume>
        <fpage>136</fpage>
        <lpage>141</lpage>
        <pub-id pub-id-type="pmid">9202065</pub-id>
      </element-citation>
    </ref>
    <ref id="B19">
      <label>19</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>von Greyerz</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Bultemann</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Schnyder</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Burkhart</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Lotti</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Hari</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Pichler</surname>
            <given-names>WJ</given-names>
          </name>
        </person-group>
        <article-title>Degeneracy and additional alloreactivity of drug-specific human alpha beta(+) T cell clones</article-title>
        <source>Int. Immunol.</source>
        <year>2001</year>
        <volume>13</volume>
        <fpage>877</fpage>
        <lpage>885</lpage>
        <pub-id pub-id-type="pmid">11431418</pub-id>
      </element-citation>
    </ref>
    <ref id="B20">
      <label>20</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Nassif</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Bensussan</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Dorothee</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Mami-Chouaib</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Bachot</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Bagot</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Boumsell</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Roujeau</surname>
            <given-names>JC</given-names>
          </name>
        </person-group>
        <article-title>Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis</article-title>
        <source>J. Invest. Dermatol.</source>
        <year>2002</year>
        <volume>118</volume>
        <fpage>728</fpage>
        <lpage>733</lpage>
        <pub-id pub-id-type="pmid">11918724</pub-id>
      </element-citation>
    </ref>
    <ref id="B21">
      <label>21</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pichler</surname>
            <given-names>WJ</given-names>
          </name>
        </person-group>
        <article-title>Modes of presentation of chemical neoantigens to the immune system</article-title>
        <source>Toxicology</source>
        <year>2002</year>
        <volume>181–182</volume>
        <fpage>49</fpage>
        <lpage>54</lpage>
      </element-citation>
    </ref>
    <ref id="B22">
      <label>22</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rich</surname>
            <given-names>RL</given-names>
          </name>
          <name>
            <surname>Day</surname>
            <given-names>YS</given-names>
          </name>
          <name>
            <surname>Morton</surname>
            <given-names>TA</given-names>
          </name>
          <name>
            <surname>Myszka</surname>
            <given-names>DG</given-names>
          </name>
        </person-group>
        <article-title>High-resolution and high-throughput protocols for measuring drug/human serum albumin interactions using BIACORE</article-title>
        <source>Anal. Biochem.</source>
        <year>2001</year>
        <volume>296</volume>
        <fpage>197</fpage>
        <lpage>207</lpage>
        <pub-id pub-id-type="pmid">11554715</pub-id>
      </element-citation>
    </ref>
    <ref id="B23">
      <label>23</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>von Rechenberg</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Blake</surname>
            <given-names>BK</given-names>
          </name>
          <name>
            <surname>Ho</surname>
            <given-names>YS</given-names>
          </name>
          <name>
            <surname>Zhen</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Chepanoske</surname>
            <given-names>CL</given-names>
          </name>
          <name>
            <surname>Richardson</surname>
            <given-names>BE</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Kery</surname>
            <given-names>V</given-names>
          </name>
        </person-group>
        <article-title>Ampicillin/penicillin-binding protein interactions as a model drug-target system to optimize affinity pull-down and mass spectrometric strategies for target and pathway identification</article-title>
        <source>Proteomics</source>
        <year>2005</year>
        <volume>5</volume>
        <fpage>1764</fpage>
        <lpage>1773</lpage>
        <pub-id pub-id-type="pmid">15761956</pub-id>
      </element-citation>
    </ref>
    <ref id="B24">
      <label>24</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ji</surname>
            <given-names>ZL</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Yu</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Han</surname>
            <given-names>LY</given-names>
          </name>
          <name>
            <surname>Zheng</surname>
            <given-names>CJ</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>YZ</given-names>
          </name>
        </person-group>
        <article-title>In silico search of putative adverse drug reaction related proteins as a potential tool for facilitating drug adverse effect prediction</article-title>
        <source>Toxicol. Lett.</source>
        <year>2006</year>
        <volume>164</volume>
        <fpage>104</fpage>
        <lpage>112</lpage>
        <pub-id pub-id-type="pmid">16563668</pub-id>
      </element-citation>
    </ref>
    <ref id="B25">
      <label>25</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Gao</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Kang</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Yu</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Luo</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Shen</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>TarFisDock: a web server for identifying drug targets with docking approach</article-title>
        <source>Nucleic Acids Res.</source>
        <year>2006</year>
        <volume>34</volume>
        <fpage>W219</fpage>
        <lpage>W224</lpage>
        <pub-id pub-id-type="pmid">16844997</pub-id>
      </element-citation>
    </ref>
    <ref id="B26">
      <label>26</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Need</surname>
            <given-names>AC</given-names>
          </name>
          <name>
            <surname>Motulsky</surname>
            <given-names>AG</given-names>
          </name>
          <name>
            <surname>Goldstein</surname>
            <given-names>DB</given-names>
          </name>
        </person-group>
        <article-title>Priorities and standards in pharmacogenetic research</article-title>
        <source>Nat. Genet.</source>
        <year>2005</year>
        <volume>37</volume>
        <fpage>671</fpage>
        <lpage>681</lpage>
        <pub-id pub-id-type="pmid">15990888</pub-id>
      </element-citation>
    </ref>
    <ref id="B27">
      <label>27</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Green</surname>
            <given-names>SA</given-names>
          </name>
          <name>
            <surname>Cole</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Jacinto</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Innis</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Liggett</surname>
            <given-names>SB</given-names>
          </name>
        </person-group>
        <article-title>A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor</article-title>
        <source>J. Biol. Chem.</source>
        <year>1993</year>
        <volume>268</volume>
        <fpage>23116</fpage>
        <lpage>23121</lpage>
        <pub-id pub-id-type="pmid">7901205</pub-id>
      </element-citation>
    </ref>
    <ref id="B28">
      <label>28</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gorre</surname>
            <given-names>ME</given-names>
          </name>
          <name>
            <surname>Mohammed</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Ellwood</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Hsu</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Paquette</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Rao</surname>
            <given-names>PN</given-names>
          </name>
          <name>
            <surname>Sawyers</surname>
            <given-names>CL</given-names>
          </name>
        </person-group>
        <article-title>Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification</article-title>
        <source>Science</source>
        <year>2001</year>
        <volume>293</volume>
        <fpage>876</fpage>
        <lpage>880</lpage>
        <pub-id pub-id-type="pmid">11423618</pub-id>
      </element-citation>
    </ref>
  </ref-list>
</back>
